Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...
Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...
Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback